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Abstract
The genetic mapping of drug-response traits is often characterised by a poor signal-to-noise ratio that is placebo related and which dis-
tinguishes pharmacogenetic association studies from classical case-control studies for disease susceptibility. The goal of this study was to
evaluate the statistical power of candidate gene association studies under different pharmacogenetic scenarios, with special emphasis on the
placebo effect. Genotype/phenotype data were simulated, mimicking samples from clinical trials, and response to the drug was modelled as a
binary trait. Association was evaluated by a logistic regression model. Statistical power was estimated as a function of the number of single
nucleotide polymorphisms (SNPs) genotyped, the frequency of the placebo ‘response’, the genotype relative risk (GRR) of the response
polymorphism, the strategy for selecting SNPs for genotyping, the number of individuals in the trial and the ratio of placebo-treated to drug-
treated patients. We show that: (i) the placebo ‘response’ strongly affects the statistical power of association studies — even a highly
penetrant drug-response allele requires at least a 500-patient trial in order to reach 80 per cent power, several-fold more than the value
estimated by standard tools that are not calibrated to pharmacogenetics; (ii) the power of a pharmacogenetic association study depends
primarily on the penetrance of the response genotype and, when this penetrance is ﬁxed, power decreases for larger placebo effects;
(iii) power is dramatically increased when adding markers; (iv) an optimal study design includes a similar number of placebo- and drug-
treated patients; and (v) in this setting, straightforward haplotype analysis does not seem to have an advantage over single marker analysis.
Keywords: trial design, single nucleotide polymorphism, haplotype, power, simulation
Introduction
Pharmacogenetics (PGx) — the study of how genetic differ-
ences inﬂuence the variability in patients’ response to drugs
1
—
investigates genes ideally covering all of the drug’s interactions
in the course of its passage through the body.
2
The objective of
PGx research is to identify the genetic proﬁle contributing to an
individual’s response pattern to a speciﬁc drug. Little is known
about the genetic basis of differential drug response. There are
examples where a single gene may exert a dominant effect on
treatment efﬁcacy, as in the case of cytochrome P4502D6
(CYP2D6), where deﬁcient patients need to be identiﬁed
before treatment initiation by codeine and its derivatives due to
efﬁcacy loss.
3
More commonly, the phenotype of drug response
is classiﬁed as multifactorial, as it generally results from the
interaction of a number of different genetic, as well as
environmental, factors. An example of this is the efﬁcacy of
clozapine therapy in the treatment of schizophrenia.
4
Traditionally, genetic mapping can be approached either by
linkage (family-based) methods or by association study
(population-based) designs. The latter are particularly likely to
play a prominent role in pharmacogenetics, as it may be dif-
ﬁcult to collect informative families with multiple patients
treated with the same drugs. The simplest and most widely
applied strategy of association studies is the case-control
design; however, several key aspects distinguish PGx associ-
ation studies from standard disease-oriented case-control
studies. First, PGx association studies are usually based on
either prospective or ongoing clinical trials, where, classically,
patients are randomly assigned to one of two groups: a treat-
ment group, receiving the tested drug; and a control group,
receiving placebo (randomised, controlled study). As a result,
the number of responders (‘cases’) can only be determined
once the study has been completed and not a priori, compli-
cating the recruitment of the required cohort. Secondly, PGx
association studies in general, and those of medications for
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psychiatric and immunological diseases in particular, are
characterised by a poor signal-to-noise ratio: approximately
one third of the patients enrolled in efﬁcacy trials may respond
to placebo treatment. The placebo ‘response’ in randomised
clinical trials includes such statistical artefacts as regression to
the mean,
5
drift in measurement of the response over time and
bias of expectations by both patients and evaluators, as well as
real effects such as spontaneous recovery, a tendency to seek
treatment outside the study and the response to additional
attention and concern arising from participation in clinical
trials.
6
Although a systematic review of placebo versus no
treatment found little evidence for placebo effect,
7
one issue
seems unquestionable: the placebo effect is present in clinical
practice and in clinical trials — by whichever name we choose
to call it or the nature of the phenomenon — and its ampli-
tude may vary with drug treatment.
6
Therefore, the impact of
placebo effects on statistical power in the context of PGx
association studies needs to be evaluated and quantiﬁed.
Several factors have been shown to inﬂuence power esti-
mations for association studies, such as: disease penetrance and
prevalence; the net effect of the susceptibility locus; the fre-
quency of the disease allele(s); the frequency of the marker
allele(s); and the extent of linkage disequilibrium (LD) between
disease alleles and marker alleles.
8,9
At present, there are no
analytical derivations of power estimation that handle more
realistic situations, such as complex dependencies between
linked markers and the disease-causing allele frequency,
recombination hot spots etc. Therefore, the strategy of choice is
simulations. Long and Langley
10
pursued this strategy to
quantify the power of complex trait association studies across a
wide range of settings using a large number of simulations.
They simulated genotypes based on the coalescent model,
11
phenotypeswere randomised, with phenotype probability being
conditioned on the causative single nucleotide polymorphism
(SNP) genotypes, and association was evaluated using appro-
priate statistical tools. The study concluded that greater power
was achieved by increasing the sample size than by increasing
the number of polymorphisms, and that marker-based tests
were more powerful than simple haplotype-based analyses.
PGx studies differ considerably from standard case-control
association studies, however, as illustrated above and conﬁrmed
by our results; hence, it is important to quantify the statistical
powerof association studies in the context of PGx and tomap the
parameter spaceof such studies. Powerestimation forPGx studies
has been previously studied by Cardon et al.,
12
who used ana-
lytical formulae to study simplistic trial designs. They explored
how different properties of SNPs, for example the frequency
of the disease-causing alleles, might inﬂuence the required size
and expected power of the clinical trial. Unfortunately, for PGx
studies — as for complex trait associations — the frequencies
of these phenotype-causing variants are unknown and their
distribution is complex,motivating a simulation-based approach.
The goal of this study was to evaluate the power of PGx
association studies under different scenarios, with special
emphasis on the placebo effect. The setting was a drug clinical
trial consisting of a double-blind, randomised controlled study,
which included a placebo-treated control group and a drug-
treated group. SNPs for a candidate gene region were then
genotyped in these groups and tested for association with the
response phenotype under the assumption of complete LD.
Drug response was simplistically treated as a binary trait, and
marker allele frequencies were then compared between
responders (cases) and non-responders (controls), similar to a
case-control design nested within a cohort.
13
Power was esti-
mated by simulation, as in the study by Long and Langley,
10
and association was evaluated using a logistic regression
model.
14,15
Since a considerable fraction of responders were
expected to respond, due to the placebo phenocopy (an
indistinguishable phenotype unrelated to the tested causative
allele), we focused on the interaction between genotype and
drug/placebo labelling. The model we propose assumes that
speciﬁc genotypes have differential effects in the drug-treated
group but not in the placebo-treated group.
12
Thus, the
logistic regression term, which is expected to indicate true
association, is the interaction term for genotype by drug.
Various studies (eg Gauderman
16
) have calculated the required
sample size for studies of gene–environment interactions, but
the methods suggested are usually applicable to very speciﬁc
designs and calculations are presented for speciﬁc sets of par-
ameters and are therefore not directly applicable to the PGx
context and the particular design of interest (randomised
controlled study).
Power was estimated over a wide range of experimental
design parameters: ﬁrst and foremost, the number of individ-
uals that participated in the clinical trial, the magnitude of the
placebo effect and the penetrance of the response locus. We
further examined direct (typing the causative allele itself) versus
indirect (typing a tightly correlated SNP) tests and haplotype
versus single marker frequency analyses. We also changed the
ratio between the sizes of placebo- and drug-treated patient
groups, the number of SNPs and the method for choosing
those SNPs (either randomly or categorised in allele frequency
bins).
9,17
Combined, our analyses provide a comprehensive
examination of the parameter space for PGx study designs.
Materials and methods
For each setting of parameters, we evaluated power as the
fraction of simulations, out of R ¼ 100 or 1,000 (see below)
repetitions, in which true association was detected, with an
expected type I error of 5 per cent. Each of the R simulations
was performed as outlined below:
. Generate genotype data
. Generate phenotype data
. For indirect tests, select SNPs for study
. Assess association between marker alleles/haplotypes and
phenotype.
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Parameters tested
We evaluated statistical power, as a function of the number (N)
of individuals in the clinical trial (N ¼ 100 to N ¼ 1,500),
under a range of different parameter settings:
. The frequency ( f
0
¼ 15 per cent to f
0
¼ 40 per cent) of
the placebo-response phenocopy. Importantly, this
magnitude of the placebo effect is assumed to equal the
penetrance (frequency of response) among homozygotes
for the non-response allele.
. The size ratio between drug- and placebo-treated patient
groups (either by suggesting a different study design — ie
ﬁxing the total number of patients — or by suggesting
drug-only follow-up studies, ﬁxing the number of
placebo-treated individuals).
. The genotype relative risk (GRR) of the response poly-
morphism (2 to 4). GRR is deﬁned as the ratio between
the penetrance among homozygotes for the response
allele ( f
2
) and homozygotes for the non-response allele
(or placebo effect, f
0
).
18
. The number of SNPs examined (M ¼ 3 or M ¼ 5).
. The strategy for SNP selection (randomly or by frequency
categories).
Generation of genotype data
The coalescent approach
11
was used to generate samples
consisting of completely linked SNPs. A simple population
genetic model involving only mutation and random genetic
drift was assumed, without recombination within the small
region considered. We simulated a ﬁxed number of sites, using
the ms software (see Hudson
19
for further details on haplotype
generation). A single realisation of the coalescent process
resulted in a set of haplotypes for 50 polymorphic sites. Sites
were correlated, as expected by sites in complete LD. One of
the sites was randomly chosen as the response site. The only
requirement was that the frequency of its minor allele was
more than 5 per cent. To further simplify the model, the
ancestral allele was assigned as the aetiological allele. Haplo-
types were then randomly paired to form genotypes.
Generation of phenotypic data
Patients were randomly assigned to the drug- or placebo–
treated group with equal probability, or according to a ﬁxed
drug/placebo group size ratio. Patients assigned to the placebo
group were randomly deﬁned as responders or non-respon-
ders, with the probability of the former equal to the ‘placebo
effect’. Patients assigned to the drug group were randomly
labelled responder/non-responder, with the probability of
response determined by the penetrance of each genotype. For
the non-response homozygotes, this probability was equal to
the placebo effect. The penetrance of the heterozygote was set
to the mean of the two homozygote penetrances, representing
an additive mode of inheritance.
Strategy for SNP selection
M ¼ 3 or M ¼ 5 markers out of the 50 simulated markers in
the candidate region were selected for genotyping. The
number of SNPs per gene was limited to adhere to the budget
constraints of the experimental design and, more importantly,
availability: SNPs must be known (as if mined from public
databases), technically typeable and polymorphic in the study
population(s). The causative SNP was not explicitly excluded
and could appear as one of the markers. Two strategies were
tested for selecting the SNPs for genotyping:
. Category approach. In the presence of LD, adequate
matching of allele frequencies at marker and trait loci
determines if a marker site will be useful for detecting an
association with the trait variant.
9,17
Following this prin-
ciple, SNPs were classiﬁed into three or ﬁve distinct cat-
egories by their minor allele frequencies. One SNP from
each category was then selected at random. If one category
was empty of SNPs, we ‘walked’ along the chromosome
until hitting a SNP with a frequency not already present in
the selected set. The frequency categories were: 0.1–0.2,
0.2–0.35 and 0.35–0.5 for M ¼ 3 markers; and 0.05–0.1,
0.1–0.2, 0.2–0.3, 0.3–0.4, 0.4–0.5 for M ¼ 5 markers.
. Random approach. M different SNPs with minor allele fre-
quencies greater than 10 per cent (for M ¼ 3) or 5 per cent
(for M ¼ 5) were randomly chosen from the entire dataset.
Two SNPs were allowed to have equal minor allele
frequencies.
Detecting association between markers
and drug response
Association was detected by a logistic regression model com-
monly used to analyse categorical data. We used the com-
mercially available SAS statistical software.
20
In this analysis,
the log odds of being a responder was regressed on the inde-
pendent variables. The model contained two independent
variables — a ‘drug’ indicator variable D (drug or placebo)
and the genotype variable G (having three possible values: 0, 1
or 2) — and the interaction between them (D*G), namely
Log odds ¼ b
0
þ b
1
Dþ b
2
G þ b
3
D*G;
where b
0
is the intercept and b
i
(i ¼ 1 to 3) is the change in log
odds as a result of a unit increase in D, G, or D
*
G, respectively.
Association was detected by a signiﬁcant ( p , 0.05) drug by
genotype interaction effect. Intuitively, this is just a more
general version of implementing an association test of respon-
ders versus non-responders in a drug-only experimental
design, while accounting for the level of the placebo
phenocopy, known from a separate, placebo-only design.
Two approaches were considered:
. A ‘direct association’ approach, in which potential drug-
response variants were tested one at a time. The suspected
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causative SNP was therefore the only genotype considered
in the logistic regression model. In this approach,
R ¼ 1,000 iterations were performed.
. An ‘indirect association’ approach, in which several markers
(three or ﬁve) were typed, hopefully turning out to be
signiﬁcantly correlated with the response locus. Genotypes
of all of the SNPs were therefore considered in the logistic
regression model, either marker by marker (testing each of
the three or ﬁve SNPs with separate regression models and
recording the highest statistic, as explained below) or as
haplotypes. The individual contribution of each SNP
varied, as expected between different random runs of the
simulation process, and we focused on the overall signiﬁ-
cance of association. The signiﬁcance of single-marker
association was computed through a Monte Carlo per-
mutation approach
21
and compared with haplotype anal-
ysis. For all indirect marker-based tests, which employed a
Monte Carlo procedure
22
for power estimation, R ¼ 100
was used, due to the computationally intensive nature of
this analysis.
To assess the signiﬁcance of single-marker association, we
applied logistic regression analysis to each genotyped marker
and recorded the highest statistic (Wald x
2
) for the drug by
genotype interaction term. We randomly permuted the
response labels and repeated the same analysis 500 times to
obtain the distribution of the maximum x
2
score under the
null hypothesis of no association. The p value for a given
simulation was estimated according to this distribution.
Haplotype analysis was more straightforward, since it did
not require maximisation over many single marker scores. In
this case, the logistic regression model included haplotypes and
drug by haplotype terms, instead of the respective genotype
terms. A haplotype variable assumes a value in {0,1,2},
denoting its copy number in the genotype of an individual.
Haplotypes are assumed to be resolved by pedigrees or
computation (eg Stephens et al.
23
). Note that the combination
of complete LD and the selection of non-redundant SNPs
implied that there are exactly M þ 1 haplotypes. R ¼ 1,000
simulations were run.
Type I error
Naturally, power should be compared when the false-positive
rates are ﬁxed to be the same across different methods. The
statistical tests performed in these simulations were designed to
hold the type I error at a constant rate of 5 per cent. To
validate the rate of our type I error, simulations were run with
GRR equal to 1 — ie f
2
was equal to the placebo effect. The
proportion of false associations was then recorded for the
different tests: direct analysis on the causative effect, the single-
marker Monte Carlo permutation approach and the haplotype
analysis for N ¼ 500 and N ¼ 1,000. The probability of
detecting a false association was estimated when the placebo
effect was 26 per cent (as in GRR ¼ 3). The results of this
validation benchmark are shown in Table 1. Note that the
variance in false-positive rates for random SNPs seemed to be
higher than that for haplotypes.
Comparison with predictions by existing tools
In order to compare the numbers obtained in this study with a
scenario in which there was no placebo effect, power was
calculated with the ‘Genetic Power Calculator’ (GPC) pro-
gram,
24
for a ‘classical’ case-control study. The parameters
were set as follows: GRR ¼ 2, f
2
¼ 0.4, f
0
¼ 0.2, frequency of
the response allele and marker allele ¼ 0.7 (which is the mean
frequency resulting from the coalescent simulation), complete
LD, prevalence of response among drug-treated individuals ¼
0:34ð0:7 £ 0:7 £ 0:4þ 2 £ 0:7 £ 0:3 £ 0:3þ 0:3 £ 0:3 £ 0:2Þ;
and a case:control ratio of 1.
Results
We ﬁrst examined the power under the optimistic assumption
of detecting direct association (ie the tested marker is the
Table 1. Estimated false-positive rates for the different statistical tests.
Number of persons False-positive rates
Direct association Indirect association
Single marker Haplotype
Categories Random
500 0.045 M ¼ 3 0.06 0.06 0.051
M ¼ 5 0.03 0.08 0.039
1,000 0.042 M ¼ 3 0.04 0.05 0.046
M ¼ 5 0.06 0.01 0.04
M is number of markers typed.
The effect of placebo on the power of pharmacogenetic association studies ReviewPRIMARY RESEARCH
q HENRY STEWART PUBLICATIONS 1479 – 7364. HUMAN GENOMICS . VOL 2. NO 1. 28–38 MARCH 2005 31
causative SNP). In Figure 1a, power is plotted as a function of
the total number of persons participating in the clinical trial
(half placebo-treated and half drug-treated) for different
penetrance scenarios. Even for the best penetrance-scenario
examined (GRR ¼ 3 and placebo effect f
0
¼ 26.6 per cent),
more than 500 individuals are required to be included in the
clinical trial to reach the standard level of 80 per cent power.
This is in sharp contrast to the predictions of the GPC,
24
which are an order of magnitude smaller than the worst
penetrance scenario examined (in Figure 1a, compare GPC
[plotted in dashed curve] and GRR with f
2
¼ 0.4, f
0
¼ 0.2).
Another observation is that the power curves are sorted
according to the penetrance of the response genotype, f
2
. This
may be expected, given that GRR ¼ f
2
=f
0
and that the
prevalence of response is a function of f
2
, and f
0
. To better
evaluate the relative impact of the penetrances f
2
and f
0
on
power, in Figure 1b we plotted the power as a function of these
parameters for a ﬁxed number (N ¼ 1,000) of persons per trial.
Fixing each of these penetrance parameters reveals that the
power, across its dynamic range, is almost a linear function of
the other penetrance. We can observe that for a given value of
f
2
, power decreases approximately linearly as f
0
increases.
Moreover, for a given value of f
0
, power increases approxi-
mately linearly as function of f
2
at most of the power ranges. In
addition, for a given GRR ratio, power is considerably
affected by the value of f
2
. Thus, considering the parameter
space deﬁned in our simulations, power for f
2
¼ 0.4, 0.6 or
0.8, and GRR ¼ 2, is 0.39, 0.644 and 0.881, respectively.
Figure 2 presents the effect of different drug/placebo group
size ratios on power for the best penetrance scenario in Figure
1a (GRR ¼ 3, f
2
¼ 0.8, f
0
¼ 0.266). Figure 2a refers to the
scenario where a ﬁrst clinical trial including drug- and pla-
cebo-treated groups has been completed and, in order to
enlarge the sample size, drug-only follow-up studies are
included in subsequent analyses. We therefore used a ﬁxed
number of placebo-treated individuals and increased the size of
Figure 1. (a) The effect of genotype relative risk (GRR) ratio
and placebo effect ( f
0
) on the power of detecting an association
between the causative single nucleotide polymorphism (SNP)
and the response to the drug. Power estimates are plotted
against the number of persons per trial for different values of f
2
(penetrance among homozygotes for the response allele), f
0
and GRR values. GPC refers to the Genetic Power Calculator
program, which does not take into account the placebo effect.
The horizontal broken line denotes the 80 per cent power
threshold. (b) The relative effect of f
2
and f
0
on the power of
detecting an association between the causative SNP and the
response to the drug. The number of persons per trial equals
1,000. Results are based on 1,000 simulations.
Figure 2. The effect of increasing the ratio between the drug
and placebo group sizes on the power of detecting an associ-
ation between the causative single nucleotide polymorphism
and the response to the drug. Estimated power is plotted
against the number of persons who received placebo for the
different drug to placebo group size ratios: 1:1 –V–; 2:1 –B–;
4:1 - -O- -. The results are based on 1,000 simulations. Geno-
type relative risk ¼ 3, f
2
¼ 0.8, f
0
¼ 0.266. The results are pre-
sented as a function of: (a) the number of placebo-treated
individuals (mimicking a drug-only follow-up); (b) the number of
individuals in the entire trial.
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the cohort of drug-treated patients. Plots of power versus
study size for different ratios (1:1, 2:1 or 4:1) between placebo-
and drug-treated group sizes are shown. Worst and inter-
mediate penetrance scenarios in Figure 1a were also analysed
(data not shown). Increasing the number of drug-treated
patients improved power only minimally (usually 10–25 per
cent for the ﬁrst doubling and an additional ,15 per cent for
the second). Improvement was largest for the less powered
scenario (data not shown). To evaluate the best design for a
PGx association study when the number of patients is limited,
we calculated power for 1:1, 2:1 and 1:2 drug-/placebo-
treated group size ratios for the same GRR/f
2
/f
0
scenarios as
in Figure 2a, but this time ﬁxing the total number of patients
participating in the clinical trial. While the best ratio seems to
be 1:1, and the worst 2:1, differences are small and often
statistically insigniﬁcant (Figure 2b).
We next evaluated power for the indirect approach — ie
the tested marker is distinct from the response SNP (Figures
3–5). The power curve for analysis, including the causative
SNP, is also presented for comparison. In Figure 3, we com-
pared power for two different strategies for selecting the
markers to be genotyped, either randomly or by categories
(see Methods section for details), examining three penetrance
scenarios and two options for the number of markers typed
(M ¼ 3 or M ¼ 5). Only for the most empowered setting
(Figure 3f ) did the ‘categories strategy’ show a consistent
advantage over the ‘random strategy’.
Comparing power obtained for the different number M of
markers typed on the same simulated datasets yielded similar
plots, with enhanced power for M ¼ 5 over M ¼ 3 (Figure 4).
This improvement is large for larger study sizes and it is sig-
niﬁcant (see grey-shaded patches in Figure 4), even for the
modest number of performed simulations when the study size
is increased.
We used the same datasets (categories strategy) to compare
the relative power of haplotype versus single marker analysis
(Figure 5). Perhaps surprisingly, straightforward haplotype
analysis does not seem to have an advantage over single marker
analysis (which seems superior in the scenarios examined in
Figures 5b and 5f). Furthermore, neither of the power plots
for graphs 5a–f indicate statistically signiﬁcant differences
between these analytical approaches.
Discussion
We have shown that the attributes characteristic of a clinical
trial, particularly the magnitude of the placebo effect, have
unexpected implications on the statistical power of PGx
association studies. Our simulation results stand in sharp con-
trast to the over-optimistic predictions of tools designed pri-
marily for case-control disease association studies
24
and
highlight the marked impact that a substantial placebo effect
can have on reducing study power. In the absence of analytical
tools speciﬁcally tailored to calculate power in the PGx context,
where gene–environment interactions are integrated our
results can only be compared with tools designed for classical
disease association studies. The simulation study presented
here shows that even under the most favourable scenario —
involving high penetrance conditions — reliable association (80
per cent power) between SNPs in a candidate gene or region
and the response to a drug requires the recruitment of an
‘optimal number’ — N < 500 patients — in a clinical trial,
given that the causative SNP is genotyped, and N < 800
patients when ﬁve perfectly linked markers are genotyped
(Figure 4). Despite the fact that for some results regarding the
indirect association approach the standard errors are still large
(due to limited number of simulations performed), a general
trend is nevertheless visible. It is hence crucial to take the
marked impact of the placebo effect on power into consider-
ation in PGx studies. Our empirical approach allows explora-
tion of a complex array of practical issues of study design, in
contrast to previous, theoretical, simplistic studies.
12
Therefore,
the results presented here are meant to guide the optimal
integration of genotype data into ongoing clinical trials and to
deﬁne the size of such a trial required for a PGx study.
In practice, once a beneﬁcial effect of a new treatment is
clearly demonstrated, patients on placebo treatment are shifted
to real therapeutic regimens. Hence, the total size of a given
placebo-treated cohort will often remain limited, while the
number of drug-treated patients will potentially signiﬁcantly
increase. We report in this study that the optimal study design in
the presence of a placebo effect under the models examined
comprises an equal number of drug- and placebo-treated
patients, as is usually the case in Phase III clinical trials. Adding
more drug-treated patients, even four times as many, increases
power only mildly. This is in sharp contrast to the more classical
case-control studies aimed at the elucidation of the aetiology
of common diseases, where the number of affected cases is the
limiting variable and where signiﬁcant gains in power could be
obtained by increasing the size of the control group.
9
We
speculate that the rationale for this differential impact of relative
cohort sizes is that in PGx it is essential to evaluate the pene-
trance for the non-causative genotype ( f
0
), which is negligible
in disease susceptibility, and therefore the number of placebo-
treated individuals becomes a tighter bottleneck.
A further potential improvement for the study design is an
educated selection of markers. Ideally, markers need to be
chosen in such a manner as to improve the chances of
matching the causative allele frequency.
8,9
Yet, the latter is
unknown (ie whether common as proposed under the
‘common-disease, common-variant hypothesis’
25
) or less fre-
quent, as also advocated.
26
Even though detailed haplotype
maps
27
are well underway, which may eventually allow SNP
selection based on phylogenetic analysis
28
or haplotype
blocks,
29
until such data are understood, one is still restricted
to choosing markers from a modest set of validated SNPs,
often with allele frequencies being the only additional data
available. In this study, we spread marker frequencies over the
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possible range of informative alleles (.5 per cent or .10 per
cent). We compared this strategy with that of choosing
markers randomly. Surprisingly, little difference in power is
reported, if at all. One possible explanation might be that
redundant markers are not the major source of power loss
when only a small set of markers is used, as these SNPs are
likely to fall in different allele frequency categories by chance.
Yet our results suggest that power is greatly increased if ﬁve
markers (M ¼ 5) are typed instead of three (M ¼ 3) (Figure 4),
as with case-control association studies. This is likely to
stem from the increased chances, as M gets larger, of hitting a
marker allele which is in phase with the response allele. Since
Figure 3. The effect of strategy for selecting markers (M, at random or categorised) on the power of detecting an association between
the markers and the response to the drug. The results are based on 100 simulations. Estimated power is shown for the causative single
nucleotide polymorphism (SNP) (–x–), randomly selected SNPs (–B–) and a categories-based strategy (–O–). (a) M ¼ 3, genotype
relative risk (GRR) ¼ 3, f
2
¼ 0.6, f
0
¼ 0.2; (b) M ¼ 5, GRR ¼ 3, f
2
¼ 0.6, f
0
¼ 0.2; (c) M ¼ 5, GRR ¼ 3, f
2
¼ 0.8, f
0
¼ 0.266; (d) M ¼ 5,
GRR ¼ 4, f
2
¼ 0.8, f
0
¼ 0.2; (e) M ¼ 3, GRR ¼ 4, f
2
¼ 0.8, f
0
¼ 0.2; (f) M ¼ 5, GRR ¼ 4, f
2
¼ 0.8, f
0
¼ 0.2.
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the number of individuals participating in a clinical trial is
limited, increasing the number of genotyped markers may be
the strategy of choice, and the only feature controlled by study
designers, for improving the power of a PGx association study.
In this study, we also considered the option of improving
power by a higher-level analysis of the genotypic data.
Our simulations extend earlier results in a complex-trait
context
10,29
to the PGx framework, regarding similarity of
power in analysis based on haplotypes versus single markers.
More sophisticated analysis of haplotypes, exploiting their
cladistic structures, may, however, be more advantageous in
PGx than in other areas,
30,31
yet the impacts of a departure
from the inﬁnite site model (an assumption implicit in
our coalescent simulation) and of homoplasy remain to be
Figure 4. The effect of the number (M) of markers typed (three or ﬁve) on the power of detecting an association between the
markers and the response to the drug. The results are based on 100 simulations. The estimated power is shown for M ¼ 3 (–V–),
M ¼ 5 (–B–) and the causative single nucleotide polymorphism (–x–). The shaded regions denote designs for which the difference
between M ¼ 3 and M ¼ 5 is signiﬁcant. (a) Random selection, genotype relative risk (GRR) ¼ 3, f
2
¼ 0.6, f
0
¼ 0.2; (b) Categories
strategy, GRR ¼ 3, f
2
¼ 0.6, f
0
¼ 0.2; (c) Random selection, GRR ¼ 3, f
2
¼ 0.8, f
0
¼ 0.266; (d) Categories strategy, GRR ¼ 3, f
2
¼ 0.8,
f
0
¼ 0.266; (e) Random selection, GRR ¼ 4, f
2
¼ 0.8, f
0
¼ 0.2; (f) Categories strategy, GRR ¼ 4, f
2
¼ 0.8, f
0
¼ 0.2.
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calibrated. These results place another pin on the map of the
literature on haplotype versus single marker analyses, each
method having its own advantages.
10,29,32,33
The frequency of the response allele is an important deter-
minant of the power of association studies.
8,29
Since this aspect
of association studies has been extensively analysed, however,
we avoid handling this issue, relying instead on existing analysis.
Simulation assumptions in this study consider a very basic
genetic model: an equilibrium population with only mutation
and random genetic drift modifying a non-recombinant
Figure 5. The effect of haplotype analysis versus one single nucleotide polymorphism (SNP) analysis on the power of detecting an
association between the markers and the response to the drug. The results are based on 100 simulations for marker analysis and 1,000
simulations for haplotype analysis. Markers (M) were chosen according to frequency categories. The estimated power is shown for the
causative SNP (–x–), haplotype analysis (–B–) and single marker (–O–) analysis. (a) M ¼ 3, genotype relative risk (GRR) ¼ 3,
f
2
¼ 0.6, f
0
¼ 0.2; (b) M ¼ 5, GRR ¼ 3, f
2
¼ 0.6, f
0
¼ 0.2; (c) M ¼ 5, GRR ¼ 3, f
2
¼ 0.8, f
0
¼ 0.266; (d) M ¼ 5, GRR ¼ 4, f
2
¼ 0.8,
f
0
¼ 0.2; (e) M ¼ 3, GRR ¼ 4, f
2
¼ 0.8, f
0
¼ 0.2; (f) M ¼ 5, GRR ¼ 4, f
2
¼ 0.8, f
0
¼ 0.2.
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haplotype block containing the candidate gene under study.
Real life is far more complex. Nonetheless, this model is
already sufﬁcient to indicate the general trends of the factors
that may confound PGx studies. While this simple model does
not accurately reﬂect samples drawn from human populations,
we consider it preferable to more assumptive, but often still
controversial, models. Incorporating other factors, such as
recombination, gene conversion, recurrent mutations or
demographic expansion, into the coalescent model is likely to
deteriorate the power estimated in the present study. It should
be noted that we make implicit assumptions in the manner in
which simulations are laid out. First, the response allele is
assumed to be the ancestral, usually more common, one. This
assumption is rationalised by our focus on drugs that, by
default, do evoke a response, by contrast with long-shot
treatments whose success is the exception and which require
separate analysis. Furthermore, the range of minor allele fre-
quencies that are examined in this work may bias our ﬁndings.
The simulation parameters analysed implicitly focus this work
at more common SNPs, more akin to the common-disease,
common-variant scenario. Other excluded factors relevant
speciﬁcally to a PGx power study — such as multiple drug
doses, quantitative or categorical outcomes instead of a binary
response, different models for placebo effect, allelic hetero-
geneity, epistatic interactions and genotyping errors — all
motivate further research. Lastly, studies of adverse drug
effects, which are not examined in the current study, may
require further research involving this particular design.
The interest of large pharmaceutical companies in PGx
studies, the strong possibility that new drugs will be required to
be evaluated for PGx by the Food and Drugs Administration
and the public demand for more personalised medicines is likely
to increase the number of PGx studies in the near future. To
increase the likelihood of obtaining signiﬁcant results, studies
need to be designed to take into consideration the parameters
that affect power estimation. The present study implies that
simple transpositions of conventional case-control models and
power evaluations to PGx are not straightforward and require
separate consideration.While statistical power in PGx is affected
by some parameters, as with disease susceptibility studies, the
particularities of a study design that is based on a clinical trial
change the set of controllable parameters and transform the
landscape of success probabilities. The follow-ups suggested
above are expected to further reﬁne the outline characteristics
of statistical power in PGx studies of drug response.
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